Acorda Therapeutics, Inc.
ACORQ
OTC PK
| Weiss Ratings | ACORQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | -- | |||
| Risk Index | -- | |||
| Risk Grade | -- | |||
| Reward Grade | -- | |||
| Rating Factors | ACORQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | -- | |||
| Efficiency Index | -- | |||
| Solvency Index | -- | |||
| Total Return Index | -- | |||
| Volatility Index | -- | |||
| Beta / Standard Deviation | ACORQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.05 | |||
| Price History | ACORQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 0.00% | |||
| 30-Day Total Return | 0.00% | |||
| 60-Day Total Return | 0.00% | |||
| 90-Day Total Return | 0.00% | |||
| Year to Date Total Return | 0.00% | |||
| 1-Year Total Return | -99.32% | |||
| 2-Year Total Return | -99.88% | |||
| 3-Year Total Return | -99.96% | |||
| 5-Year Total Return | -99.99% | |||
| 52-Week High % Change | -99.44% | |||
| 52-Week Low % Change | 2.66% | |||
| Price | ACORQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $2.40 | |||
| 52-Week Low Price | $0.01 | |||
| 52-Week Low Price (Date) | Aug 20, 2024 | |||
| 52-Week High Price (Date) | Apr 03, 2024 | |||
| Valuation | ACORQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | -- | |||
| Enterprise Value | -- | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -212.10 | |||
| Earnings Per Share Growth | 202.98% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.00 | |||
| Price/Book (Q) | 0.00 | |||
| Enterprise Value/Revenue (TTM) | 1.61 | |||
| Price | $0.01 | |||
| Enterprise Value/EBITDA (TTM) | 338.61 | |||
| Enterprise Value/EBIT | -7.75 | |||
| Market Cap Category | -- | |||
| Dividends and Shares | ACORQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 1.24M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ACORQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 914 347 4300 | |||
| Address | 2 Blue Hill Plaza Pearl River, NY 10965 | |||
| Website | www.acorda.com | |||
| Country | United States | |||
| Year Founded | 1995 | |||
| Profitability | ACORQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -20.82% | |||
| Profit Margin | -227.75% | |||
| Management Effectiveness | ACORQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -6.60% | |||
| Return on Equity | -- | |||
| Income Statement | ACORQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 115.66M | |||
| Total Revenue (TTM) | 115.66M | |||
| Revenue Per Share | $93.13 | |||
| Gross Profit (TTM) | 95.19M | |||
| EBITDA (TTM) | 551.00K | |||
| EBIT (TTM) | -24.08M | |||
| Net Income (TTM) | -263.43M | |||
| Net Income Avl. to Common (TTM) | -263.43M | |||
| Total Revenue Growth (Q YOY) | -8.85% | |||
| Earnings Growth (Q YOY) | -62.83% | |||
| EPS Diluted (TTM) | -212.10 | |||
| EPS Diluted Growth (Q YOY) | -62.85% | |||
| Balance Sheet | ACORQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 9.36M | |||
| Cash Per Share (Q) | $7.54 | |||
| Total Current Assets (Q) | 48.45M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -185.77M | |||
| Current Ratio (Q) | 0.216 | |||
| Book Value Per Share (Q) | -$149.56 | |||
| Total Assets (Q) | 81.58M | |||
| Total Current Liabilities (Q) | 223.94M | |||
| Total Debt (Q) | 195.92M | |||
| Total Liabilities (Q) | 267.35M | |||
| Total Common Equity (Q) | -185.77M | |||
| Cash Flow | ACORQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -264.00K | |||
| Cash from Financing (TTM) | -- | |||
| Net Change in Cash (TTM) | -27.42M | |||
| Levered Free Cash Flow (TTM) | 6.01M | |||
| Cash from Operations (TTM) | -27.15M | |||
